Login / Signup

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.

Mona Amini-AdleN KhanaferM Le-BouarG DuruS DalleL Thomas
Published in: BMC cancer (2018)
This is the largest series of unselected patients treated in real-life with anti-PD-1 as second-or-higher line of treatment. Anti-PD-1 was less effective in BRAF-mutated cases as a majority of patients presented aggressive tumor evolution after BRAFi discontinuation. These data are consistent with previous studies suggesting a negative impact of BRAFi prior to immunotherapy.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • metastatic colorectal cancer
  • stem cells
  • machine learning
  • cell therapy
  • data analysis
  • case control